Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00608959 · ClinicalTrials.gov registry record · Phase 3
Study of Antimicrobial Activity of Omiganan 1% Gel vs. Chlorhexidine 2% for Topical Skin Antisepsis in Healthy Adult Subjects
A Phase 3 study of Infection, sponsored by Cadence Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00608959 is a Phase 3 study of Infection that has completed, run by Cadence Pharmaceuticals. The registered enrollment target is 30 participants, below the 726-participant average among 41 other Infection trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00608959, a Phase 3 study of Infection, has completed, sponsored by Cadence Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to determine if omiganan 1% gel (the investigational medication in this research study) is effective and safe when compared to chlorhexidine 2% (an FDA approved medication) for killing bacteria (germs) that live on the surface of the skin. Both of the study medications are applied topically (on the surface of the skin).
Conditions Studied
Interventions
- DRUG omiganan 1% gel
- DRUG chlorhexidine 2% solution
Study Locations (1)
Montana
- BioSciences Lab - Bozeman
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2008-05 |
| Est. Completion | 2008-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00608959
The ClinicalTrials.gov registry entry for NCT00608959 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 726-participant average among 41 other Infection trials with a reported enrollment target (96% lower). The listed sponsor is Cadence Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Infection appearing as the primary indexed condition, and to 2 interventions - of which omiganan 1% gel is the first listed.
NCT00608959 reports 1 study location spanning 1 distinct geographic area - top geographies include Montana.
Frequently Asked Questions
What is clinical trial NCT00608959 about?
NCT00608959 is a clinical study titled "Study of Antimicrobial Activity of Omiganan 1% Gel vs. Chlorhexidine 2% for Topical Skin Antisepsis in Healthy Adult Subjects". The purpose of this research study is to determine if omiganan 1% gel (the investigational medication in this research study) is effective and safe when compared to chlorhexidine 2% (an FDA approved medication) for killing bacteria (germs) that live on the surface of the skin. Both of the study medi...
What is the current status of trial NCT00608959?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2008-05. Estimated completion is 2008-06.
What conditions does trial NCT00608959 study?
This clinical trial studies the following conditions: Infection.
What interventions are being tested in trial NCT00608959?
The interventions under investigation include: omiganan 1% gel (DRUG), chlorhexidine 2% solution (DRUG).
Who is sponsoring clinical trial NCT00608959?
This trial is sponsored by Cadence Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00608959 being conducted?
This trial has 1 study location across Montana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study)
COMPLETED · Phase 3
-
Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers
COMPLETED · Phase 3
-
Home Hospital for Suddenly Ill Adults
RECRUITING · NA
-
Copper Supplementation in Cirrhosis
RECRUITING · NA
-
Persona Revision Knee System Outcomes
RECRUITING
-
NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.